Clinical Trials in Pretoria, Gauteng
2 recruiting
Showing 1–4 of 4 trials
Recruiting
Phase 3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Breast Neoplasms
Merck Sharp & Dohme LLC1,200 enrolled257 locationsNCT06312176
Recruiting
Phase 3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled234 locationsNCT06966700
Recruiting
Phase 3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie698 enrolled316 locationsNCT04928846
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868